PTPN6 and colorectal carcinoma: Our data therefore identifies SHP-1 as a druggable target of regorafenib verified by the evidence that regorafenib pharmacologically increases SHP-1 activity through relieving the inhibitory N-SH2 domain of SHP-1, leading to reduced p-STAT3Tyr705 level and eventual suppression of EMT in CRC cells (Figure 4C).